19 studies found for:    newlink
Show Display Options
Rank Status Study
1 Recruiting Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
Conditions: Glioblastoma Multiforme;   Glioma;   Gliosarcoma;   Malignant Brain Tumor
Interventions: Drug: Indoximod;   Drug: Temozolomide
2 Terminated IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
Conditions: Breast Cancer;   Lung Cancer;   Melanoma;   Pancreatic Cancer;   Solid Tumors
Intervention: Drug: 1-methyl-D-tryptophan
3 Recruiting IDO Inhibitor Study for Advanced Solid Tumors
Conditions: Solid Tumors;   Breast Cancer;   Lung Cancer;   Pancreatic Cancer
Intervention: Drug: NLG919
4 Recruiting Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Docetaxel;   Other: Placebo;   Drug: Indoximod
5 Terminated Vaccine Treatment for Advanced Breast Cancer
Condition: Breast Cancer
Intervention: Biological: HyperAcute - Breast cancer vaccine
6 Recruiting Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Conditions: Pancreatic Cancer;   Pancreatic Carcinoma Non-resectable;   Locally Advanced Malignant Neoplasm
Interventions: Drug: FOLFIRINOX;   Biological: Algenpantucel-L Immunotherapy;   Radiation: 5-FU Chemoradiation;   Drug: Gemcitabine;   Drug: Capecitabine;   Drug: Nab-Paclitaxel
7 Terminated Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Biological: HyperAcute-Lung Cancer Vaccine
8 Terminated Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
9 Completed Vaccine Treatment for Advanced Malignant Melanoma
Condition: Malignant Melanoma
Intervention: Biological: HyperAcute-Melanoma Vaccine
10 Recruiting Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Conditions: Metastatic Pancreatic Adenocarcinoma;   Metastatic Pancreatic Cancer
Interventions: Drug: Nab-Paclitaxel;   Drug: Gemcitabine;   Drug: Indoximod
11 Active, not recruiting Immunotherapy Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Biological: HyperAcute-Pancreas Immunotherapy;   Drug: Gemcitabine;   Radiation: 5FU Chemoradiation
12 Recruiting Study of IDO Inhibitor in Combination With Ipilimumab for Adult Patients With Metastatic Melanoma
Conditions: Metastatic Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Drug: Indoximod;   Drug: Ipilimumab
13 Active, not recruiting Vaccine Study for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute(R)-Pancreatic Cancer Vaccine
14 Completed Vaccine Treatment for Hormone Refractory Prostate Cancer
Condition: Prostate Cancer
Intervention: Biological: HyperAcute-Prostate Cancer Vaccine
15 Recruiting Immunotherapy Study for Patients With Stage IV Melanoma
Conditions: Stage IV Melanoma;   Metastatic Melanoma
Interventions: Drug: HyperAcute®-Melanoma (HAM) Immunotherapy;   Drug: Ipilimumab
16 Recruiting Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer;   Progression of Non-small Cell Lung Cancer;   Non-small Cell Lung Cancer Recurrent
Interventions: Drug: Docetaxel;   Biological: HyperAcute®-Lung Immunotherapy;   Drug: Gemcitabine;   Drug: Pemetrexed
17 Not yet recruiting Immunotherapy Study for Metastatic Renal Cell Cancer
Conditions: Metastatic Renal Cell Carcinoma;   Metastatic Clear-cell Renal Cancer;   Recurrent Renal Cell Carcinoma;   Refractory Renal Cell Carcinoma;   Metastatic Kidney Cancer
Intervention: Biological: HyperAcute®-Renal (HAR) Immunotherapy
18 Completed Vaccine Treatment for Surgically Resected Pancreatic Cancer
Condition: Pancreatic Cancer
Intervention: Biological: HyperAcute-Pancreatic Cancer Vaccine
19 Unknown  A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma
Condition: Melanoma
Interventions: Biological: HyperAcute vaccine;   Drug: Pegylated Interferon-Alpha 2b

Indicates status has not been verified in more than two years